<SEC-DOCUMENT>0001193125-25-145721.txt : 20250624
<SEC-HEADER>0001193125-25-145721.hdr.sgml : 20250624
<ACCEPTANCE-DATETIME>20250624160531
ACCESSION NUMBER:		0001193125-25-145721
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250624
DATE AS OF CHANGE:		20250624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oric Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001796280
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				471787157
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-287949
		FILM NUMBER:		251068989

	BUSINESS ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 388-5600

	MAIL ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d10137d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-287949 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g10137g13u34.jpg" ALT="LOGO" STYLE="width:3.33584in;height:0.934042in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ORIC Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>19,230,845 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and resale from time to time of up to 19,230,845 shares of our common stock, par value $0.0001 per share
(the &#147;<B>Shares</B>&#148;), by the selling stockholders identified in this prospectus, including their transferees, pledgees or donees or their respective successors (the &#147;<B>selling stockholders</B>&#148;), which consist of (i) 14,130,313
outstanding shares of our common stock held by the selling stockholders and (ii) 5,100,532 shares of our common stock issuable upon the exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our
common stock. The shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants were issued and sold to the selling stockholders in a private placement (the &#147;<B>Private Placement</B>&#148;)<B> </B>pursuant to a
securities purchase agreement among us and such selling stockholders dated May&nbsp;23, 2025 (the &#147;<B>Purchase Agreement</B>&#148;). We are registering the Shares being offered hereunder pursuant to such Purchase Agreement on behalf of the
selling stockholders, to be offered and sold by them from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of the Shares covered by this prospectus does
not mean that the selling stockholders will offer or sell any of the Shares. Sales of the Shares by the selling stockholders may occur at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices or
at negotiated prices. The selling stockholders may sell Shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling stockholders, the purchasers of
the Shares, or both. We are paying the cost of registering the Shares covered by this prospectus as well as various related expenses. The selling stockholders will bear all fees, discounts, concessions or commissions of broker-dealers or agents, and
any other expenses incurred in connection with the offering of the Shares by the selling stockholders. See &#147;<I>Plan of Distribution</I>&#148; beginning on page 13 of this prospectus for more information about how the selling stockholders may
sell their Shares. Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;ORIC.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for this and future filings.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves risks. Please carefully read the information under the headings &#147;<A HREF="#tx10137_4">Risk Factors</A>&#148; beginning on page 5 of this prospectus and &#147;Item 1A &#150; Risk&nbsp;Factors&#148; of our most recent report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or <FONT STYLE="white-space:nowrap">10-Q</FONT> that is incorporated by
reference in this prospectus before you invest in our securities. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is June 20, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_3">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_5"><FONT STYLE="white-space:nowrap">Forward-Looking</FONT>
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_7">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_8">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_9">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_10">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_11">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx10137_12">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the United States
Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) using a &#147;shelf&#148; registration process. Under this shelf registration process, the selling stockholders may, from time to time, offer and sell the Shares described in this
prospectus in one or more offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should only rely on the information contained in or incorporated by reference into this
prospectus (as supplemented and amended), along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. No person has been authorized to give any information or make any
representations other than those contained in or incorporated by reference into this prospectus (as supplemented and amended) and, if given or made, such information or representations must not be relied upon as having been authorized by us. Your
reliance on any unauthorized information or representation is at your own risk. This prospectus (as supplemented and amended) shall not constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which
it is unlawful for such person to make such an offering or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the entire prospectus (as supplemented and
amended) and any related free writing prospectus, as well as the documents incorporated by reference into this prospectus, before making an investment decision. The information contained in this prospectus, and in any supplement or amendment to this
prospectus or any related free writing prospectus, or the documents incorporated by reference herein and therein, are accurate only as of their respective dates, regardless of the time of delivery of this prospectus, any supplement or amendment to
this prospectus or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information that is presented in greater detail elsewhere, or incorporated by reference, in this
prospectus. It does not contain all of the information that may be important to you and your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including the matters set forth in the section
titled &#147;Risk Factors&#148; and the financial statements and related notes and other information that we incorporate by reference herein, including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports
on Form 10-Q. Unless the context indicates otherwise, references in this prospectus to &#147;ORIC Pharmaceuticals, Inc.,&#148; &#147;we,&#148; &#147;our&#148; and &#147;us&#148; refer, collectively, to ORIC Pharmaceuticals, Inc., a Delaware
corporation. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company dedicated to improving patients&#146; lives
by<I>&nbsp;<U>O</U></I><I>vercoming</I><I></I><I>&nbsp;<U>R</U></I><I>esistance</I><I></I><I>&nbsp;<U>I</U></I><I>n</I><I></I><I>&nbsp;<U>C</U></I><I>ancer</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our fully integrated discovery and development team is advancing a diverse pipeline of innovative clinical and discovery stage therapies
designed to counter resistance mechanisms in cancer by leveraging our expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical stage product candidates include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ORIC-944,</FONT> an allosteric inhibitor of the polycomb repressive complex 2
(&#147;<B>PRC2</B>&#148;) via the embryonic ectoderm development subunit, for which we licensed development and commercialization rights from Mirati Therapeutics, Inc. with a license agreement. We filed and cleared an Investigational New Drug
(&#147;<B>IND</B>&#148;) with the Food and Drug Administration (&#147;<B>FDA</B>&#148;) for <FONT STYLE="white-space:nowrap">ORIC-944</FONT> in the fourth quarter of 2021. We completed a Phase 1b trial of
<FONT STYLE="white-space:nowrap">ORIC-944</FONT> as a single-agent, in patients with advanced prostate cancer and reported initial Phase 1b data from this trial in January 2024, demonstrating potential <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> drug properties, including an approximate <FONT STYLE="white-space:nowrap">20-hour</FONT> clinical half-life, robust target engagement and a favorable safety profile. In July&nbsp;2024, we
announced that in the first half of 2024 we initiated dosing of <FONT STYLE="white-space:nowrap">ORIC-944</FONT> in combination with apalutamide as well as in combination with darolutamide, as part of the ongoing Phase 1b trial in patients with
metastatic castration resistant prostate cancer (&#147;<B>mCRPC</B>&#148;). We also announced that we entered into clinical trial collaboration and supply agreements with Janssen Research&nbsp;&amp; Development, LLC, a Johnson and Johnson company
(&#147;<B>Johnson</B><B></B><B>&nbsp;&amp; Johnson</B>&#148;) and Bayer Consumer Care AG (&#147;<B>Bayer</B>&#148;), to evaluate <FONT STYLE="white-space:nowrap">ORIC-944</FONT> in combination with Erleada<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (&#147;<B>apalutamide</B>&#148;), Johnson&nbsp;&amp; Johnson&#146;s androgen receptor (&#147;<B>AR</B>&#148;) inhibitor and Nubeqa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
(&#147;<B>darolutamide</B>&#148;), Bayer&#146;s AR inhibitor. In January 2025, we reported early Phase 1b combination data from the dose escalation cohort of <FONT STYLE="white-space:nowrap">ORIC-944</FONT> in combination with 240 mg
(&#147;<B>QD</B>&#148;) apalutamide in patients with mCRPC. We reported dose escalation data of <FONT STYLE="white-space:nowrap">ORIC-944</FONT> both in combination with apalutamide and in combination with darolutamide in May 2025, which we expect
will be followed by an additional update in the second half of 2025. We also expect to report dose optimization data in combination with AR inhibitor(s) in the fourth quarter of 2025 or first quarter of 2026. We expect to initiate our first Phase 3
trial for <FONT STYLE="white-space:nowrap">ORIC-944</FONT> in mCRPC in the first half of 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ORIC-114,</FONT> a brain penetrant, orally bioavailable, irreversible inhibitor
that selectively targets epidermal growth factor receptor (&#147;<B>EGFR</B>&#148;) exon 20, human epidermal growth factor receptor 2 (&#147;<B>HER2</B>&#148;) exon 20 and EGFR atypical mutations, for which we licensed development and
commercialization rights from Voronoi Inc. with a license and collaboration agreement. In the fourth quarter of 2021, we filed a Clinical Trial Application (&#147;<B>CTA</B>&#148;) in South Korea for <FONT STYLE="white-space:nowrap">ORIC-114,</FONT>
which was cleared in the first quarter of 2022. We also filed and cleared an IND with the FDA for <FONT STYLE="white-space:nowrap">ORIC-114</FONT> in the third quarter of 2022. We are enrolling a Phase 1b trial of
<FONT STYLE="white-space:nowrap">ORIC-114</FONT> as a single-agent, in patients </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
with advanced solid tumors with EGFR and HER2 exon 20 insertion mutations, EGFR atypical mutations or HER2 amplifications, which allows enrollment of patients with central nervous system
metastases that are either treated or untreated but asymptomatic. We reported initial Phase 1b data from this trial at the European Society for Medical Oncology Congress in October 2023, which demonstrated both systemic and intracranial activity
across multiple dose levels in a heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> patient population. In April&nbsp;2024, we announced the selection of two provisional recommended Phase 2 dose levels of
<FONT STYLE="white-space:nowrap">ORIC-114</FONT> at 80 mg and 120 mg daily QD. We expect to report a comprehensive data update during the second half of 2025 that will include <FONT STYLE="white-space:nowrap">ORIC-114</FONT> in the first-line EGFR
exon 20 monotherapy cohort, the 2L+ EGFR atypical cohort and cohorts for 2L EGFR exon 20 and 2L+ HER2 exon 20. In January 2025, we announced that we entered into a clinical trial and supply agreement with Johnson&nbsp;&amp; Johnson, to evaluate <FONT
STYLE="white-space:nowrap">ORIC-114</FONT> in combination with subcutaneous amivantamab for the first line treatment of patients with advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;<B>NSCLC</B>&#148;) with EGFR
exon 20 insertion mutations, and we initiated a Phase 1b trial in the first quarter of 2025. Initial data from this trial in addition to <FONT STYLE="white-space:nowrap">ORIC-114</FONT> data as a monotherapy in first-line EGFR atypical mutations are
expected in <FONT STYLE="white-space:nowrap">mid-2026.</FONT> We also expect to initiate Phase 3 trial(s) for <FONT STYLE="white-space:nowrap">ORIC-114</FONT> in first-line NSCLC in 2026, in EGFR exon 20, HER2 exon 20, and/or atypical EGFR
mutations. Beyond these clinical stage product candidates, we are developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in August 2014. Our principal executive offices are located at 240&nbsp;E.&nbsp;Grand Avenue, 2nd Floor, South San Francisco, California 94080. Our telephone number is
<FONT STYLE="white-space:nowrap">(650)&nbsp;388-5600.</FONT> Our website address is www.oricpharma.com. Information contained on the website is not incorporated by reference into this prospectus or any other filings we make with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use the ORIC Pharmaceuticals logo and other marks as trademarks in the United States and other countries. This prospectus and the documents
incorporated herein may contain references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in such documents, including logos, artwork and other visual
displays, may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbol, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or
the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any
other entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;23, 2025, in connection with the Private Placement, we entered into the Purchase Agreement with the selling stockholders named in this prospectus. Under the terms of the Purchase Agreement, we agreed to prepare and file a registration
statement for purposes of registering the resale of the Shares, to use our commercially reasonable efforts to have such registration statement declared effective within the time period set forth in the Purchase Agreement, and to keep such
registration statement effective for up to two years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the Private Placement, on May&nbsp;29, 2025 we sold and issued to
certain of the selling stockholders (i) 14,130,313 shares of our common stock at a purchase price of $6.50 per share and (ii)&nbsp;5,100,532&nbsp;shares of our common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock at a purchase price of $6.4999 per share and an exercise price of $0.0001&nbsp;per share. The total purchase price paid by the selling stockholders in
the Private Placement was approximately $125&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer and sale of the securities in the Private Placement were not
registered under the&nbsp;Securities Act&nbsp;of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), or any state securities laws. We relied on an exemption from the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration requirements of the&nbsp;Securities Act&nbsp;provided by Section&nbsp;4(a)(2) thereof and Rule 506(b) of Regulation&nbsp;D promulgated thereunder. Each of the selling stockholders
has represented to us that such selling stockholder is an &#147;accredited investor,&#148; as defined in&nbsp;Regulation&nbsp;D of the&nbsp;Securities Act,&nbsp;and that the securities purchased by such selling stockholder were being acquired solely
for such selling stockholder&#146;s own account and for investment purposes and not with a view to its future sale or distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the Purchase Agreement, which was filed as an exhibit to our Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on
May&nbsp;28, 2025. See &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Incorporation by Reference</I>.&#148; The representations, warranties and covenants made by us in the Purchase Agreement were made solely for the benefit of
the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties thereto, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or
covenants were made as of an earlier date. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock registered for sale by selling stockholders </P></TD>
<TD>19,230,845 Shares, consisting of 14,130,313 outstanding shares of our common stock held by the selling stockholders and 5,100,532 shares of our common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the Shares by the selling stockholders. Upon any exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants by payment of cash, however, we will receive the exercise price of
such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. See &#147;<I>Use of Proceeds</I>&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering price </P></TD>
<TD>The selling stockholders may sell all or a portion of their Shares through public or private transactions at prevailing market prices or at privately negotiated prices. See &#147;<I>Plan of Distribution</I>&#148; for additional information.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;<I>Risk Factors</I>&#148; section included in or incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;ORIC&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should
carefully consider the specific risks, uncertainties and assumptions discussed in Part I, Item 1A &#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Part II, Item 1A &#147;Risk
Factors&#148; in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> each as may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future, all of which are incorporated by
reference into this prospectus in their entirety, together with other information in this prospectus, including any information incorporated or deemed to be incorporated by reference herein. The risks and uncertainties we have described are not the
only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. See the sections titled &#147;<I>Where You Can Find More Information</I>&#148; and
&#147;<I>Incorporation by Reference</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_5"></A><FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT> STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any prospectus supplement and the information incorporated by reference herein may contain certain statements that
constitute &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.
The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148;
&#147;plan,&#148; &#147;potentially,&#148; &#147;likely,&#148; and similar expressions and variations thereof are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Such forward-looking
statements include statements regarding the intent, belief or current expectations of our management that are subject to known and unknown risks, uncertainties and assumptions. You are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Forward-looking statements contained in this
prospectus, any prospectus supplement and the information incorporated by reference herein include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other
positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of preclinical studies and clinical trials for
<FONT STYLE="white-space:nowrap">ORIC-944,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114</FONT> and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related
preparatory work, the period during which the results of the trials will become available, and our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope and likelihood of regulatory filings and approvals, including timing of IND or CTA applications
and final FDA approval of <FONT STYLE="white-space:nowrap">ORIC-944,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114</FONT> and any other future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of and activity under the company&#146;s collaboration, licenses and other third-party
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope or likelihood of foreign regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and advance our current product candidates and programs into, and successfully complete,
clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our manufacturing, commercialization, and marketing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of
focus and sales strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to hire additional personnel and our ability to attract and retain such personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of a global pandemic or other public health emergencies on our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the market opportunity for our product candidates, including our estimates of the number of patients
who suffer from the diseases we are targeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the approval and use of our product candidates in combination with other drugs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the success of competing therapies that are or may become available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of the number of patients that we will enroll in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the further development of our product candidates, including additional indications we may
pursue; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing regulations and regulatory developments in the United States, Europe and other jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position, including the scope of protection we are able to establish and maintain for
intellectual property rights covering <FONT STYLE="white-space:nowrap">ORIC-944,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114</FONT> and other product candidates we may develop, including the extensions of existing patent terms where available,
the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for
the manufacture of our product candidates for preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that
may be necessary or desirable to develop, manufacture or commercialize our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of <FONT STYLE="white-space:nowrap">ORIC-944,</FONT>
<FONT STYLE="white-space:nowrap">ORIC-114</FONT> and other product candidates we may develop, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of
<FONT STYLE="white-space:nowrap">ORIC-944,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114</FONT> and other product candidates we may develop, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period over which we estimate our existing cash, cash equivalents and investments will be sufficient to fund
our operating plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the
Jumpstart Our Business Startups Act of 2012; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of our existing resources. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you
should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in
the forward-looking statements. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we do not plan to publicly update or revise any forward-looking statements contained
herein after we distribute this prospectus, whether as a result of any new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and although we believe such
information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available
relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference in this prospectus may contain market data that we obtain from industry sources.
These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a
number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this prospectus, actual results may differ from the projections. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are filing the registration statement of which this prospectus is a part to permit holders of the Shares described in the section entitled
&#147;<I>Selling Stockholders</I>&#148; to resell such Shares. We are not selling any securities under this prospectus and we will not receive any proceeds from the sale or other disposition of the Shares held by the selling stockholders. Upon any
exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants by payment of cash, however, we will receive the exercise price of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. The selling stockholders will receive
all of the proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders will pay any discounts, commissions, fees of underwriters, selling
brokers or dealer managers and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the Shares. We will bear all other costs, fees
and expenses incurred in effecting the registration of the shares of our common stock covered by this prospectus, including, without limitation, all registration and filing fees, printing fees, Nasdaq listing fees and fees and expenses of our
counsel and our accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the possible resale by certain of our stockholders, who we refer to in this prospectus as the &#147;selling
stockholders,&#148; of up to 19,230,845 Shares, which consist of (i) 14,130,313 outstanding shares of our common stock held by the selling stockholders and (ii) 5,100,532 shares of our common stock issuable upon the exercise of outstanding <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock that are held by the selling stockholders. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original
issuance and will not expire. We cannot predict when or whether any of the selling stockholders will exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. See &#147;<I>Prospectus Summary&#151;Private Placement</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants provide that a holder of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants does not have the right to exercise <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding
immediately before or after giving effect to such exercise (the &#147;<B>Beneficial Ownership Limitation</B>&#148;); provided, however, that each holder may increase the Beneficial Ownership Limitation by giving notice to the company, but not in
excess of 19.99%. Throughout this prospectus, when we refer to the shares of common stock being registered on behalf of the selling stockholders, we are referring to the outstanding shares of our common stock and the shares issuable upon the
exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants without giving effect to the Beneficial Ownership Limitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides the names of the selling stockholders and the number of Shares offered by such selling stockholders under this
prospectus. The selling stockholders listed below have previously been granted registration rights with respect to the Shares offered hereby pursuant to that Purchase Agreement dated as of May&nbsp;23, 2025, by and between us and the purchasers
named therein. The Shares offered by this prospectus may be offered from time to time by the selling stockholders listed below. The selling stockholders are not obligated to sell any of their Shares offered by this prospectus, and reserve the right
to accept or reject, in whole or in part, any proposed sale of Shares. The selling stockholders listed below may also offer and sell less than the number of Shares indicated. The selling stockholders are not making any representation that any Shares
covered by this prospectus will or will not be offered for sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of Shares and percentages of beneficial ownership set forth
below are based on 85,224,191 shares of our common stock outstanding as of May&nbsp;29, 2025. Beneficial ownership is determined under the SEC rules and regulations and generally includes voting or investment power over securities. We have prepared
the table based on information given to us by, or on behalf of, the selling stockholders. The selling stockholders may sell all, some or none of the shares of common stock subject to this prospectus. See &#147;<I>Plan of Distribution</I>&#148; as
may be supplemented and amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock set forth below for each selling stockholder
includes (i)&nbsp;all shares of our common stock beneficially held by such selling stockholder as of May&nbsp;29, 2025, excluding shares issuable upon the exercise of outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants above the
Beneficial Ownership Limitation, (ii)&nbsp;the number of shares of our common stock that may be offered under this prospectus, and (iii)&nbsp;the number and percentage of our common stock beneficially owned by the selling stockholders assuming all
of the shares of our common stock registered hereunder are sold. The table below and footnotes assume that the selling stockholders will sell all of the shares listed. However, because the selling stockholders may sell all or some of their shares
under this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares that will be sold by the selling stockholders or that will be held by the selling stockholders after completion of any
sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may name additional selling stockholders from time to time. Information about such additional selling
stockholders, including their identities and the securities to be registered on their behalf, will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set forth in a prospectus supplement, in a post-effective amendment or in filings that we make with the SEC under the Exchange Act that are incorporated by reference in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Common</B><br><B>Stock Beneficially</B><br><B>Owned Prior to</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of</B><br><B>Common&nbsp;Stock</B><br><B>Being&nbsp;Offered<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Common</B><br><B>Stock to be</B><br><B>Beneficially Owned</B><br><B>After
Offering<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with SR One<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,615,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,615,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Associates, LLC<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,940,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,846,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Viking Global
Investors<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,729,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,076,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,572,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Venrock Healthcare Capital Partners<SUP
STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,596,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,307,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,289,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Growth Equity Opportunities 18 VGE,
LLC<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,118,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,923,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,195,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nextech Crossover I SCSP<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,162,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,876,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,285,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Vivo<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,126,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,046,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,080,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with NEXTBio<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">933,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates beneficial ownership of less than 1% of the total outstanding common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of our common stock in the column &#147;Number of Shares of Common Stock Being
Offered&#148; represents all of the shares of our common stock that a selling stockholder may offer and sell from time to time under this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts a selling stockholder may offer Shares for sale. The selling
stockholders might not sell any or might sell all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the Shares pursuant to this offering, and because, except as set forth elsewhere in this
prospectus, there are currently no agreements, arrangements or understandings with respect to the sale of any of the Shares, we cannot estimate the number of the Shares that will be held by the selling stockholders after completion of the offering.
However, for purposes of this table, we have assumed that, after completion of the offering, none of the Shares covered by this prospectus will be held by the selling stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,330,218 shares of common stock and 51,846 shares of common stock issuable upon the exercise
of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by SR One Capital Opportunities Fund I, LP, in the Private Placement, (ii) 1,504,976 shares of common stock and 33,485 shares of common stock issuable upon the exercise of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by AMZL, LP, in the Private Placement, and (iii) 679,735 shares of common stock and 15,124 shares of common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by SR One Capital Fund II Aggregator, LP, in the Private Placement. SR One Capital Opportunities Partners I, LP, is the general partner of SR One Capital Opportunities Fund I, LP.
SR One Capital Management, LLC (&#147;<B>Capital Management</B>&#148;), is the general partner of SR One Capital Opportunities Partners I, LP. Simeon George, MD, is the Managing Member of Capital Management. SR One Capital Opportunities Partners I,
LP, Capital Management, and Simeon George, MD, share voting and investment power with respect to the shares directly held by SR One Capital Opportunities Fund I, LP. SR One Capital Partners II, LP, is the general partner of SR One Capital Fund II
Aggregator, LP. Capital Management is the general partner of SR One Capital Partners II, LP. Simeon George, MD, is the Managing Member of Capital Management. SR One Capital Partners II, LP, Capital Management, and Simeon George, MD, share voting and
investment power with respect to the shares directly held by SR One Capital Fund II Aggregator, LP. SR One Capital SMA Partners, LP, is the general partner of AMZL, LP. Capital Management is the general partner of SR One Capital SMA Partners, LP.
Simeon George, MD, is the Managing Member of Capital Management. SR One Capital SMA Partners, LP, Capital Management, and Simeon George, MD, share voting and investment power with respect to the shares directly held by AMZL, LP. All indirect holders
of the above-mentioned shares disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary interest therein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,923,077 shares of common stock and 1,923,107 shares of common stock issuable upon the
exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by Point72 Associates, LLC in the Private Placement and (ii) 94,211 shares of common stock held by Point72 Associates, LLC prior to the Private Placement. Point72
Asset Management, L.P. maintains investment and voting power with respect to the securities held by certain investment funds it manages, including Point72 Associates, LLC. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset
Management, L.P. Mr.&nbsp;Steven&nbsp;A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. By reason of the provisions of <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> of the Exchange Act, each of
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&nbsp;Cohen may be deemed to beneficially own the securities directly held by Point72 Associates, LLC that are reflected herein. Each of Point72 Asset Management, L.P., Point72
Capital Advisors, Inc., and Mr.&nbsp;Cohen disclaims beneficial ownership of any such securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,846,182 shares of common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP (the &#147;<B>Opportunities Fund</B>&#148;) in the Private Placement,
(ii) 1,230,788 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased by Viking Global Opportunities Drawdown (Aggregator) LP (the &#147;<B>Drawdown Fund</B>&#148;) in the Private
Placement, and (iii)&nbsp;an aggregate of 6,572,700 shares of common stock held by the above referenced entities prior to the Private Placement. In accordance with the Beneficial Ownership Limitation of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the Opportunities Fund and Drawdown Fund are prohibited from exercising such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to the extent that, immediately prior to or as a
result of such exercise, the Opportunities Fund and Drawdown Fund would, together with affiliates and any persons who are members of a Section&nbsp;13(d) group with these funds or their affiliates, beneficially own more than 9.99% of the total
number of shares of common stock then issued and outstanding immediately after giving effect to the exercise. As a result, the &#147;Shares of Common Stock Beneficially Owned Prior to Offering&#148; excludes an aggregate of 920,325 shares of common
stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants due to the Beneficial Ownership Limitation. The Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which
power may be exercised by its general partner, Viking Global Opportunities Portfolio GP LLC (&#147;<B>Opportunities GP</B>&#148;), and by Viking Global Investors LP (&#147;<B>VGI</B>&#148;), which provides managerial services to Opportunities Fund.
O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities Parent GP LLC, the sole member of Viking Global Opportunities GP LLC (which
is the sole member of Opportunities GP), have shared authority to direct the voting and disposition of investments beneficially owned by VGI and Opportunities GP. The Drawdown Fund has the authority to dispose of and vote the shares directly owned
by it, which power may be exercised by its general partner, Viking Global Opportunities Drawdown Portfolio GP LLC (&#147;<B>Drawdown GP</B>&#148;), and by VGI, which provides managerial services to the Drawdown Fund. O. Andreas Halvorsen, David C.
Ott and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities Parent GP LLC, the sole member of Viking Global Opportunities Drawdown GP LLC (which is the sole member of
Drawdown GP), have shared authority to direct the voting and disposition of investments beneficially owned by VGI and Drawdown GP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,716,000 shares of common stock purchased by Venrock Healthcare Capital Partners EG, L.P.
(&#147;<B>VHCP EG</B>&#148;) in the Private Placement, (ii) 537,923 shares of common stock purchased by Venrock Healthcare Capital Partners III, L.P. (&#147;<B>VHCP III</B>&#148;) in the Private Placement, (iii) 53,769 shares of common stock
purchased by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC (&#147;<B>VHCP Co III</B>&#148;) in the Private Placement, and (iv)&nbsp;an aggregate of 4,289,193 shares of common stock held by the above referenced entities
prior to the Private Placement. VHCP Management EG, LLC (&#147;<B>VHCPM EG</B>&#148;) is the sole general partner of VHCP EG. VHCP Management III, LLC (&#147;<B>VHCPM</B>&#148;) is the sole general partner of VHCP III and the sole manager of VHCP Co
III. Dr.&nbsp;Bong Koh and Nimish Shah are the voting members of VHCPM EG and VHCPM. The address of the above referenced entities and persons is 7 Bryant Park, 23rd Floor, New York, New&nbsp;York&nbsp;10018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,923,076 shares of common stock purchased by Growth Equity Opportunities 18 VGE, LLC
(&#147;<B>GEO 18 VGE</B>&#148;) in the Private Placement and (ii)&nbsp;an aggregate of 2,195,545 shares of common stock held by GEO 18 VGE prior to the Private Placement. GEO 18 VGE is wholly owned by NEA 18 Venture
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Growth Equity, L.P. (&#147;<B>NEA 18 VGE</B>&#148;). The sole general partner of NEA 18 VGE is NEA Partners 18 VGE, L.P. (&#147;<B>NEA Partners 18 VGE</B>&#148;). The sole general partner of NEA
Partners 18 VGE is NEA VGE 18 GP, LLC (&#147;<B>NEA VGE 18 LLC</B>&#148;). The managers of NEA VGE 18 LLC are Scott D. Sandell, Anthony A. Florence, Jr., Mohamad Makhzoumi, Ali Behbahani, Carmen Chang, Edward T. Mathers, Paul E. Walker and Rick C.
Yang. NEA VGE 18 LLC and its managers may be deemed to beneficially own the securities held by Growth Equity Opportunities 18 VGE, LLC. Each of NEA VGE 18 and its managers disclaims beneficial ownership of any of the shares of our common stock they
may be deemed to beneficially own except to the extent of their respective pecuniary interest therein. The address of the above referenced entities and Scott Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD
21093. The address of Ali Behbahani, Carmen Chang, Mohamad Makhzoumi, Paul Walker and Rick Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Edward Mathers and
Anthony Florence is New Enterprise Associates, 104&nbsp;5th&nbsp;Avenue, 19th Floor, New York, NY 10001. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,876,923 shares of common stock purchased by Nextech Crossover I SCSp in the Private Placement
and (ii) 5,285,714 shares of common stock held by Nextech Crossover I SCSp prior to the Private Placement. Ian Charoub, Costas Constantinides and Rocco Sgobbo share voting and investment power over the shares held by Nextech Crossover I SCSp. The
address of Nextech Crossover I SCSp is 8 rue Lou&nbsp;Hemmer, <FONT STYLE="white-space:nowrap">L-1748</FONT> Senningerberg, Grand Duchy of Luxembourg. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 918,410 shares of common stock purchased by Vivo Opportunity Fund Holdings, L.P. in the Private
Placement, (ii) 127,744 shares of common stock purchased by Vivo Opportunity Cayman Fund, L.P. in the Private Placement, and (iii)&nbsp;an aggregate of 2,080,450 shares of common stock held by the above referenced entities prior to the Private
Placement. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The voting members of each of Vivo Opportunity, LLC and Vivo
Opportunity Cayman, LLC are Kevin Dai, Gaurav Aggarwal, Frank Kung and Shan Fu, none of whom has individual voting or investment power with respect to the shares held by Vivo Opportunity Fund Holdings, L.P. or Vivo Opportunity Cayman Fund, L.P. The
address of the individuals and entities referenced in this footnote is 192 Lytton Avenue, Palo Alto, California 94301. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 192,308 shares of common stock purchased by NEXTBio Master Fund LP in the Private Placement,
(ii) 346,154 shares of common stock purchased by NEXTBio Evergreen LLC in the Private Placement, and (iii) 395,160 shares of common stock held by NEXTBio Master Fund LP prior to the Private Placement. Hongbo Lu and Richard Klemm share voting and
investment power over the shares held by NEXTBio Master Fund LP and NEXTBio Evergreen LLC. The address of the individuals and entities referenced in this footnote is 3000 Sand Hill Road, Suite <FONT STYLE="white-space:nowrap">3-210</FONT> Menlo
Park, California 94025. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, including their transferees, pledgees or donees or their respective successors, may, from time to time, sell,
transfer or otherwise dispose of any or all of their Shares or interests in Shares on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of Shares or interests therein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the Shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales effected after the date the registration statement of which this prospectus is a part is declared
effective by the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such Shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the Shares owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Shares, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable
provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the Shares in
other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of Shares or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of our common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling
stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of
the Shares offered by this prospectus, which Shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly
or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants by payment of cash, however, we will receive the exercise price of such <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the Shares in open
market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein
may be &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the Shares may be underwriting discounts and commissions under the
Securities Act. Selling stockholders who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the Shares to be sold, the names of the selling stockholders, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the
registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the
common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from
registration or qualification requirements is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the
anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this
prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any
broker-dealer that participates in transactions involving the sale of the Shares against certain liabilities, including liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities
laws, relating to the registration of the Shares offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders to use
commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part effective and to remain continuously effective until the earlier of (i)&nbsp;the second anniversary of the effective date of the
registration statement, (ii)&nbsp;such time as all of the Shares covered by this prospectus (A)&nbsp;have been disposed of pursuant to and in accordance with such registration statement or (B)&nbsp;become eligible for resale by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> without any volume limitations or other restrictions pursuant to Rule 144(b)(1)(i) under the Securities Act or any other rule of similar effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon for us by Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional
Corporation, Palo Alto, California. Additional legal matters may be passed on for us, or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of ORIC Pharmaceuticals, Inc. as of December&nbsp;31, 2024 and 2023, and for each of the years in the <FONT
STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2024, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm,
incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at <I>www.sec.gov</I>. Copies of certain information filed by us with the SEC are also available on our website at <I>www.oricpharma.com</I>. Information accessible on or through our website is not
a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement is part of a registration statement that we filed with the SEC
and do not contain all of the information in the registration statement. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities that we are
offering. Forms of any documents establishing the terms of the offered securities are filed as exhibits to the registration statement of which this prospectus forms a part or under cover of a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and incorporated in this prospectus by reference. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference
to the document to which it refers. You should read the actual documents for a more complete description of the relevant matters. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx10137_12"></A>INCORPORATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information that we file with the SEC, which
means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are
incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated by reference in this prospectus. This means that you
must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by
reference the documents listed below and any future filings we make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents furnished pursuant to
Items 2.02 or 7.01 of any Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and, except as may be noted in any such <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> exhibits filed on such form that are related to such
information), until the offering of the securities under the registration statement of which this prospectus forms a part is terminated or completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1796280/000095017025022273/oric-20241231.htm">February<U></U>&nbsp;18,<U></U>&nbsp;2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portions of our Definitive Proxy Statement on Schedule&nbsp;
14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1796280/000119312525091359/d900756ddef14a.htm">April<U></U>&nbsp;23, 2025</A> (other than information furnished rather than filed), that
are incorporated by reference into our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K;</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31,
2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1796280/000095017025063564/oric-20250331.htm">May<U></U>&nbsp;5, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1796280/000119312525035203/d830999d8k.htm">February
<U></U>&nbsp;25, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1796280/000119312525054784/d873253d8k.htm">March<U></U>&nbsp;
14, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1796280/000119312525129531/d911818d8k.htm">May&nbsp;
28, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1796280/000119312525140725/d35600d8k.htm">June 13, 2025</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in the Registration Statement on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> relating thereto, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1796280/000119312520112233/d859615d8a12b.htm">April<U></U>&nbsp;20, 2020</A>, including any amendment or report filed for
the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by making a written or
oral request at the following address and telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ORIC Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 E. Grand Ave, 2nd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">South
San Francisco, California 94080 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) <FONT STYLE="white-space:nowrap">388-5600</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g10137g13u34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g10137g13u34.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !: 4 # 1$
M A$! Q$!_\0 'P !  (" P$! 0$           D*!P@%!@L$ P$"_\0 1Q
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M&8SV=WIBKQK#V'=68&*GNBY(X.2B*Q/'\VXMR*9,&U?")[HTH!&I]&D:GGD
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M\M6;V/XY;.WB\-&Q*VWLU*51<?DY$]GL2MP/5T,D D%ABQ")%.E2U*YXBKN
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M]EW!C)P(N> ;V+5KM>7CR)2H,@A ')$@//"<&ZSR&=7OTXTU15]>W]H?E_\
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MW8"_(@4K'_I)[)CW'L=\_6A#97:3-?5U7Z27$3%(\I 3\4A419 %C]&M.8(
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M+ F2I$Z7*FRR.+*F23RI)7_TRR)!7&,1WGZ^YY'N<[_JJ\L^ % 4#@   #R
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M:%AV(EB>,@_(AU!&I1IY7&9%!)C\C0O1L.5>G<KV48'N"&@D=2"._(.N1O\
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M =\:=7644\&?"DB7VDCRX<H8I$<XU^CQ&&PC%^CFHO-K5E=5=&5D8<JRD,K
M^15AR"#\P>-0U+%+!(\,T<D,L;%)(I4:.2-U/#*Z. RL#V*L 0?,:^)%5%14
M545%\HJ?145/T*B_[E3G]U\:_KG.<JN<Y7.7]*N555?_ ,JOE5XTU_H8WE(P
M0F/(4CVC&,;5>0CWJC6,8QJ*YSW.5&M:U%5RJB(BJO'_ -NY_ /,_DU_0"2
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M/IXY.F%FEE@0RRR2$J>3([.3W;XL2=<[_$"E3I9*2.G4K5$$C@)6@B@0 'L
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MQ$:P8A#:T8QL:B(UC&HUJ(B(B)SX))))))/<DGDD_,D^>O0JJBA$5450 JJ
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FQK?Q$1$1$1$1$1$1$\(B)]$1$3Z(B)^A.8'4C^7EK^\::<::_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
